Incyte Corporation (INCY) News Headlines

▮ More

Date

Headline

4/30/2019 8:07:16 AM Incyte To No Longer Participate In Co-funding Of Development Of Baricitinib

4/30/2019 7:18:52 AM Incyte Corporation Q1 adjusted earnings of $0.62 per share

4/30/2019 7:07:06 AM Incyte Q1 EPS $0.47; Non-GAAP EPS $0.62

4/26/2019 3:15:22 AM Biotech Stocks Facing FDA Decision In May 2019

2/21/2019 5:54:23 AM Beware Of Fake Leukemia Drug Iclusig, Warns WHO

2/14/2019 7:03:28 AM Incyte Q4 EPS $0.32 Vs Loss $0.71 Last Year

2/7/2019 7:06:28 AM Incyte Says FDA Extended Review Period For Ruxolitinib In Acute Graft-Versus-Host Disease

2/4/2019 6:52:11 AM Lilly : Baricitinib Meets Primary Endpoint In BREEZE-AD1 And BREEZE-AD2

2/4/2019 6:46:28 AM Lilly Says Baricitinib Meet Primary Endpoint In BREEZE-AD1 And BREEZE-AD2 Phase 3 Studies

1/30/2019 2:19:45 AM Biotech Stocks Facing FDA Decision In February

1/22/2019 7:30:21 AM Incyte Announces First Patient Treated In Phase 3 Clinical Trial Of Itacitinib For Chronic Graft-Versus-Host Disease

1/7/2019 7:03:34 AM Merus Says FDA Accepted IND Application For MCLA-145

1/3/2019 10:02:08 AM Incyte To Present At Goldman Sachs Conference; Webcast At 11:00 AM ET

1/3/2019 7:08:45 AM Incyte Names Christiana Stamoulis CFO - Quick Facts

1/3/2019 7:00:49 AM Incyte Appoints Christiana Stamoulis As CFO, Effective Feb 11

12/16/2018 7:57:00 PM Innovent, Incyte In Deal For Three Clinical-stage Product Candidates In China

12/13/2018 6:58:22 AM Eli Lilly : FDA Grants Fast Track Designation To Baricitinib Development Program

12/13/2018 6:53:35 AM Lilly:FDA Grants Fast Track Designation To Baricitinib Development Program For Treatment Of Systemic Lupus Erythematosus

12/3/2018 10:07:17 AM Incyte Announces Updated Results From Its Pivotal Phase 2 REACH1 Study

11/27/2018 7:30:38 AM Incyte Appoints Dashyant Dhanak As Chief Scientific Officer